Rapport Therapeutics (NASDAQ:RAPP) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its position in Rapport Therapeutics (NASDAQ:RAPP) by 77.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,170 shares of the company’s stock after purchasing an additional 3,137 shares during the period. JPMorgan Chase & Co.’s holdings in Rapport Therapeutics were worth $127,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in RAPP. KLP Kapitalforvaltning AS purchased a new position in Rapport Therapeutics in the fourth quarter valued at $34,000. New York State Common Retirement Fund acquired a new stake in shares of Rapport Therapeutics during the 4th quarter valued at about $62,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Rapport Therapeutics in the 4th quarter valued at about $138,000. Barclays PLC boosted its position in Rapport Therapeutics by 36.8% during the third quarter. Barclays PLC now owns 12,863 shares of the company’s stock worth $264,000 after purchasing an additional 3,463 shares in the last quarter. Finally, Swiss National Bank acquired a new stake in Rapport Therapeutics in the fourth quarter valued at approximately $319,000.

Insider Transactions at Rapport Therapeutics

In other news, Director Wendy B. Young purchased 6,000 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was acquired at an average price of $10.21 per share, with a total value of $61,260.00. Following the purchase, the director now directly owns 6,000 shares in the company, valued at approximately $61,260. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Troy A. Ignelzi purchased 9,900 shares of Rapport Therapeutics stock in a transaction dated Wednesday, March 12th. The shares were purchased at an average cost of $10.10 per share, for a total transaction of $99,990.00. Following the transaction, the chief financial officer now owns 9,900 shares in the company, valued at approximately $99,990. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on RAPP shares. Citizens Jmp began coverage on Rapport Therapeutics in a research note on Tuesday, April 8th. They set a “mkt outperform” rating for the company. JMP Securities began coverage on Rapport Therapeutics in a research note on Tuesday, April 8th. They set a “market outperform” rating and a $28.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $32.67.

Rapport Therapeutics Stock Down 3.1 %

Rapport Therapeutics stock opened at $10.98 on Tuesday. The firm has a market capitalization of $400.75 million and a price-to-earnings ratio of -0.79. Rapport Therapeutics has a 52-week low of $6.43 and a 52-week high of $29.74. The company has a fifty day simple moving average of $9.89 and a 200-day simple moving average of $15.80.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.